Abstract
Aims:
To compare the effectiveness of the long-acting anticholinergic, tiotropium with ipratropium/salbutamol in reducing the risk of exacerbations and COPD-related referrals in patients with COPD.
Methods:
Data were obtained from the General Practice Research Database (GPRD). Propensity score matching was used to balance prognostic covariates between treatment groups. Incidence rate ratios and 95% confidence intervals during a 12-month follow-up period were estimated.
Results:
4193 patients (3385, tiotropium; 808, ipratropium/salbutamol) in the GPRD met the inclusion/exclusion criteria. Patients treated with tiotropium had more severe COPD than patients treated with ipratropium/salbutamol. Following propensity score matching, 1222 tiotropium-treated patients and 633 ipratropium/salbutamol-treated patients were included in the final analysis. Incidence rate ratios (95% confidence intervals) were 0.74 (0.64–0.85; p=0.0086) for exacerbations and 0.57 (0.46–0.70; p=0.004) for COPD-related referrals/hospitalisations.
Conclusions:
Tiotropium is associated with a reduced risk of exacerbations and COPD-related referrals and hospitalisation compared to combined ipratropium/salbutamol in patients with COPD.
Keywords: COPD, general practice database, hospitalisation, ipratropium/salbutamol, tiotropium
Full Text
The Full Text of this article is available as a PDF (281.4 KB).
Footnotes
JG, SL and MC are employees of Boehringer Ingelheim Ltd UK. SK is an employee of Boehringer Ingelheim Corporate. DP has no shares in pharmaceutical companies. He has received speaker's honoraria for speaking at sponsored meetings from the following companies marketing respiratory products: 3M, Altana, Astra Zeneca, BI, GSK, IVAX, MSD, Novartis, Pfizer, Schering-Plough. He has received honoraria for advisory panels with; 3M, Altana, Astra Zeneca, BI, GSK, IVAX, MSD, Novartis, Pfizer, Schering-Plough. He or his research team have received funding for research projects from: 3M, Altana, Astra Zeneca, BI, GSK, IVAX, MSD, Novartis, Pfizer, Schering-Plough, Viatris.